Researchers at the Weizmann Institute of Science initiated the PERIBLOOD clinical trial, enrolling 1,500 patients globally to evaluate single-cell sequencing utility in diagnosing myelodysplastic syndromes (MDS). Collaborating with commercial partners Cliseq and 10x Genomics, the study uses non-invasive peripheral blood analyses to potentially replace or reduce the need for invasive bone marrow biopsies by providing comprehensive hematopoietic stem and progenitor cell profiling, aiming to enhance diagnostic accuracy and patient comfort.